CHChuanchao He

Chuanchao He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chuanchao He has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Jianlong Zhang

    Department of Hepatobiliary Surgery, Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou China

    3 shared publications
  • Jie Wang

    Department of Hepatobiliary Surgery, Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou China

    3 shared publications
  • Yongcong Yan

    Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    3 shared publications
  • Zhiyu Xiao

    Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    3 shared publications
  • Haohan Liu

    Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    2 shared publications
  • Zheng Chen

    Department of Gastrointestinal Surgery The Fifth Affiliated Hospital of Sun Yat‐Sen University Zhuhai Guangdong China

    2 shared publications

Latest Publications

  • JoVE Video Dataset

    by Yongcong Yan, Haohan Liu, Zhiyu Xiao, Chuanchao He

    According to extensive case analyses compiled by the Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM), patients with Pancreaticobiliary Maljunction (PBM) exhibit a significantly elevated incidence of biliary tract tumors, ranging from 34% to 39%. This rate is dramatically higher than the population-based incidence of biliary tract tumors in the general population (approximately 0.002%). Beyond malignancy, PBM is associated with multiple common pancreatobiliary disorders, including recurrent pancreatitis, stones within the common pancreatobiliary channel, and pancreatic duct stones, which substantially impair patients' quality of life. Despite its insidious nature and frequent delayed or missed diagnosis, key clinical features such as recurrent pancreatitis, acalculous cholecystitis, and extrahepatic bile duct dilation provide crucial diagnostic clues. Standard diagnostic modalities include abdominal ultrasound, computed tomography (CT), and magnetic resonance cholangiopancreatography (MRCP). Endoscopic retrograde cholangiopancreatography (ERCP) serves as the definitive diagnostic and classification tool. Upon confirmation of diagnosis, patients should undergo curative surgery to mitigate the risk of biliary tract carcinogenesis. This article provides a detailed protocol for the diagnostic and therapeutic approaches to PBM.

  • Standardized Diagnosis and Treatment of Pancreaticobiliary Maljunction

    by Yongcong Yan, Haohan Liu, Zhiyu Xiao, Chuanchao He

    According to extensive case analyses compiled by the Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM), patients with Pancreaticobiliary Maljunction (PBM) exhibit a significantly elevated incidence of biliary tract tumors, ranging from 34% to 39%. This rate is dramatically higher than the population-based incidence of biliary tract tumors in the general population (approximately 0.002%). Beyond malignancy, PBM is associated with multiple common pancreatobiliary disorders, including recurrent pancreatitis, stones within the common pancreatobiliary channel, and pancreatic duct stones, which substantially impair patients' quality of life. Despite its insidious nature and frequent delayed or missed diagnosis, key clinical features such as recurrent pancreatitis, acalculous cholecystitis, and extrahepatic bile duct dilation provide crucial diagnostic clues. Standard diagnostic modalities include abdominal ultrasound, computed tomography (CT), and magnetic resonance cholangiopancreatography (MRCP). Endoscopic retrograde cholangiopancreatography (ERCP) serves as the definitive diagnostic and classification tool. Upon confirmation of diagnosis, patients should undergo curative surgery to mitigate the risk of biliary tract carcinogenesis. This article provides a detailed protocol for the diagnostic and therapeutic approaches to PBM.


  • Open Access

    SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression

    by Zhenyu Zhou, Zheng Chen, Qianlei Zhou, Shiyu Meng, Juanyi Shi, Sintim Mui, Hai Jiang, Jianhong Lin, Gui He, Wenbin Li, et al.

    Both lysine and arginine methyltransferases are thought to be promising therapeutic targets for malignant tumors, yet how these methyltransferases function in malignant tumors, especially hepatocellular carcinoma (HCC), has not been fully elucidated. Here, we reported that SMYD4, a lysine methyltransferase, acts as an oncogene in HCC. SMYD4 was highly upregulated in HCC and promoted HCC cell proliferation and metastasis. Mechanistically, PRMT5, a well‐known arginine methyltransferase, was identified as a SMYD4‐binding protein. SMYD4 monomethylated PRMT5 and enhanced the interaction between PRMT5 and MEP50, thereby promoting the symmetrical dimethylation of H3R2 and H4R3 on the PRMT5 target gene promoter and subsequently activating DVL3 expression and inhibiting expression of E‐cadherin, RBL2, and miR‐29b‐1‐5p. Moreover, miR‐29b‐1‐5p was found to inversely regulate SMYD4 expression in HCC cells, thus forming a positive feedback loop. Furthermore, we found that the oncogenic effect of SMYD4 could be effectively suppressed by PRMT5 inhibitor in vitro and in vivo. Clinically, high coexpression of SMYD4 and PRMT5 was associated with poor prognosis of HCC patients. In summary, our study provides a model of crosstalk between lysine and arginine methyltransferases in HCC and highlights the SMYD4‐PRMT5 axis as a potential therapeutic target for the treatment of HCC.


  • Open Access

    A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3β-Signaling Pathways

    by Zheng Chen, Wei Yu, Qiming Zhou, Jianlong Zhang, Hai Jiang, Dake Hao, Jie Wang, Zhenyu Zhou, Chuanchao He, Zhiyu Xiao


  • Open Access

    ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma

    by Zhenyu Zhou, Hai Jiang, Kangsheng Tu, Wei Yu, Jianlong Zhang, Zhigang Hu, Heyun Zhang, Dake Hao, Pinbo Huang, Jie Wang, et al.

    Tumor metastasis is the major reason for poor prognosis of hepatocellular carcinoma (HCC) patients after hepatic resection. SMYD3 has been demonstrated to promote liver tumor metastasis in mice. However, the detailed molecular mechanism is still largely unknown. The effect of SMYD3 on invasiveness and metastasis of HCC was analyzed by immunohistochemistry, migration assay, invasion assay, wound healing assay and in vivo lung metastasis assay. Mass spectrometry analysis was conducted using proteins pulled down by H3K4me3 antibody in SMYD3-overexpressing cells. Luciferase reporter, chromatin immunoprecipitation, Electrophoretic mobility shift assay were used to measure the regulation of SLUG transcription by SMYD3-ANKHD1. In addition, the role of SMYD3-ANKHD1 in determining clinical outcomes for HCC patients was investigated by immunohistochemistry in 243 HCC tissues. SMYD3 was an independent prognostic factor of HCC and promoted migration and invasion of human HCC cells. ANKHD1 was identified by mass spectrometry as a co-regulator with SMYD3. ANKHD1 interacted with H3K4me3 when cells were overexpressing SMYD3. The pro-migratory and pro-invasive effects of SMYD3 were attenuated when ANKHD1 was knocked down by siRNA. Furthermore, we found that SMYD3 bound and activated the SLUG gene promoter in a manner associated with elevating H3K4me3, H3K9Ac and H3K14Ac. Knockdown of ANKHD1 could attenuate the SMYD3-dependent activation of Slug expression. We further detected the expression of SMYD3 and ANKHD1 in 243 HCC patients and found that patients with positive coexpression of SMYD3 and ANKHD1 (SMYD3+ANKHD1+) had the shortest overall and recurrence-free survival. Our findings provide a novel molecular mechanism for the SMYD3-regulated HCC migration and metastasis, and indicates that SMYD3-ANKHD1 may be a potential target for treating HCC.


  • Association of high histone H3K4 trimethylation level and prognosis of patients with low-TNM-stage hepatocellular carcinoma.

    by Junyao Xu, Chuanchao He, Jianlong Zhang, Jie Wang

    171 Background: Along with genetic events, tumor associated epigenetic alterations including DNA methylation and post-translational histone modifications are important determinants in the initiation and progression of hepatocellular cancer (HCC) and represent promising biomarkers and therapeutic targets. Locus-specific trimethylation of histone H3 lysine 4 (H3K4me) is a well-known modification linked to the enhanced transcriptional expression of many genes activated in HCC. However its expression and association with prognosis of HCC patients remain unclear. Our aim was to assess the cellular expression pattern of H3K4me3 in HCC and its association with clinicopathologic variables and outcome. Methods: Expression of H3K4me3 and the histone methyltransferase SMYD3 was studied by western blotting and immunohistochemistry in human HCC cell lines and tumor tissue micmicroarray, which is from a well–characterized series of HCC patients(n=168). Tissue staining were assessed using blinded semiquantitative scoring. The optimal cut-point of H3K4me3 expression for prognosis was determined by the X-tile program. The prognostic significance was evaluated using Kaplan-Meier survival estimates and log-rank tests. Tumor tissue micmicroarray from another independent HCC patients cohort(n=147) was used for validation studies. Results: Expression of H3K4me3 and the histone methyltransferase SMYD3 were enhanced in HCC cell lines.In clinical tumor specimens, enhanced expression of H3K4me3 was correlated with reduced overall survival (P < 0.0001), especially in early-stage HCC patients(TNM I/II).Furthermore,both univariate and multivariate analysis revealed that H3K4me3 level was a significant and independent predictor of poor survival (hazard ratio,3.592; 95% CI, 2.302-5.605). In addition, H3K4m3 expression was positively correlated with SMYD3 expression in both testing and validation cohorts (P Conclusions: H3K4me3 level defines previously unrecognized subsets of HCC patients with distinct epigenetic phenotype and clinical outcome, thus can be a novel predictor for poor prognosis of HCC patients, especially within TNM I/IIstage.